Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers

Autor: Jörg Täubel, Ulrike Lorch, Christopher S. Spencer, Anne Freier, Dorothée Camilleri, Dilshat Djumanov, Georg Ferber, Line Marchand, Jean-Pierre Gotteland, Oliver Pohl

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)

Abstract Nolasiban is an orally active oxytocin receptor antagonist being developed to increase the efficiency of assisted reproductive technologies. This study evaluated the pharmacokinetics, pharmacodynamics, and cardiac safety of nolasiban in 45 h

Externí odkaz: https://doaj.org/article/941c758ff82c46db9ab0bd9fda565dc9

Can a second booster dose be delayed in patients who have had COVID-19?

Autor: Jorg Taubel, Ulrike Lorch, D. Camilleri, Anne Freier, Christopher S. Spencer, I. Garitaonandia

Vaccination forms a key part of public health strategies to control the spread of SARS-CoV-2 globally. In the UK, two vaccines (BNT162b2-mRNA produced by Pfizer, and ChAdOx-1-S produced by Oxford-AstraZeneca) have been licensed to date, and their adm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b035f571351d59a1b14da83274fc8f9d
https://doi.org/10.1101/2021.04.09.21255200

Concentration-QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers

Autor: Ulrike Lorch, Georg Ferber, Mohamed Farouk Chughlay, Anne Freier, Christopher S. Spencer, Cristina Donini, J. Täubel, Myriam El Gaaloul, Stephan Chalon, Simon Coates

Publikováno v: British journal of clinical pharmacology. 88(1)

Aim Given the increasing emergence of drug resistance in Plasmodium, new antimalarials are urgently required. P218 is an aminopyridine that inhibits dihydrofolate reductase being developed as a malaria chemoprotective drug. Assessing the effect of ne

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60c8aac533c07e3441afe025a1c27297
https://pubmed.ncbi.nlm.nih.gov/34075612

A Phase 1 Study to Investigate the Effects of Cortexolone 17α-Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity

Autor: Anne Freier, Jorg Taubel, William Burch, Avani Patel, Christopher S. Spencer, Jørgen K. Kanters, John Camm, Georg Ferber, Alessandro Mazzetti, Claus Graff, Sara Fernandes

Publikováno v: Clinical Pharmacology in Drug Development
Täubel, J, Mazzetti, A, Ferber, G, Burch, W, Fernandes, S, Patel, A, Spencer, C S, Freier, A, Graff, C, Kanters, J K & Camm, J 2021, ' A Phase 1 Study to Investigate the Effects of Cortexolone 17α-Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity ', Clinical Pharmacology in Drug Development, vol. 10, no. 6, pp. 572-581 . https://doi.org/10.1002/cpdd.935
Taubel, J, Mazzetti, A, Ferber, G, Burch, W, Fernandes, S, Patel, A, Spencer, C S, Freier, A, Graff, C, Kanters, J K & Camm, J 2021, ' A Phase 1 Study to Investigate the Effects of Cortexolone 17 alpha-Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity ', Clinical Pharmacology in Drug Development, vol. 10, no. 6, pp. 572-581 . https://doi.org/10.1002/cpdd.935

Cortexolone 17 alpha-propionate, also known as clascoterone, is a potent androgen receptor inhibitor intended for the topical treatment of skin diseases associated with androgenic pathway alterations. In nonclinical studies, cortexolone 17 alpha-prop

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2e49f38c5b1e05e4513bfe1d56c95fc
https://pubmed.ncbi.nlm.nih.gov/33942574

RESOLVING THE NEED FOR GROUNDWATER RECHARGE VERSUS FOREST PRODUCTIVITY IN A RECLAIMED WATERSHED USING NUMERICAL MODELLING

Autor: Carl Mendoza, Christopher S Spencer, Sean K. Carey, Simon M. Landhäusser, Kevin Devito, Maxwell C. Lukenbach

Publikováno v: Geological Society of America Abstracts with Programs.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1b42b402adfc02e377940e4fdc3c71e0
https://doi.org/10.1130/abs/2017am-306440